# QSP Glaucoma v5.5 â€” Complement-Driven Neurodegeneration Dashboard

> **A quantitative systems pharmacology (QSP) model of normal-tension glaucoma (NTG) implementing the RPEâ€“DAMPsâ€“complementâ€“microglial vicious cycle with intravitreal peptide therapy intervention.**

![Status](https://img.shields.io/badge/status-active-4ADE80?style=flat-square)
![Model](https://img.shields.io/badge/model-14--state%20ODE%20RK4-A855F7?style=flat-square)
![Solver](https://img.shields.io/badge/solver-in--browser-67E8F9?style=flat-square)
![License](https://img.shields.io/badge/license-All%20Rights%20Reserved-F87171?style=flat-square)

---

## Overview

![Dashboard Overview](figures/fig0_overview.png)

This tool models the self-sustaining complement feedback loop in NTG:

```
IOP / Mechanical Stress
        â†“
    RPE death  â”€â”€â†’  DAMPs (ATP, HMGB1)
        â†“                   â†“
  [Trans-synaptic]    TLR4 / NF-ÎºB bootstrap
  RGC degeneration         â†“
   (structural,        M_mig (migrating microglia)
  drug-independent)        â†“
                   â˜… COMPLEMENT FEEDBACK LOOP â˜…
                   M1 â†’ C1q            â† Loop Node A
                          â†“
                   C4b2a convertase
                          â†“
                   C3 cleavage â†’ C3a   â† Loop Node B (CLOSES LOOP)
                          â†“                    â†“
                   C3aR â†’ M1 â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  C5a â†’ M_mig
                          â†“
                   Pro-inflam Cytokines (IL-1Î², IL-6, TNF-Î±)
                          â†“
                   Direct RGC death â† drug-accessible
```

An intravitreal peptide with three PD mechanisms (C1q block, C3aR/C5aR antagonism, M1â†’M2 switch) disrupts this loop, reducing cytokine-mediated RGC death. The model quantifies the drug-accessible fraction and its ceiling relative to the structural trans-synaptic pathway.

---

## Simulation Results

### RGC Survival & RPE Health

![RGC Survival and RPE Health](figures/fig1_endpoints.png)

The model runs a **calibrated 180-day simulation** (optimised auto-converged at iteration 20). Five intravitreal injections (â–¶ purple dashed lines, days 0/7/14/21/28) drive progressive peptide accumulation. The treated arm diverges from control as complement loop suppression accumulates, reaching +11â€“12 pp RGC protection by day 180.

---

### Complement Loop Node Activity â€” C1q, C3a, M1

![Complement Loop Nodes](figures/fig2_loop_nodes.png)

The peptide's PD1 mechanism (C1q block) interrupts Loop Node A, collapsing C3a production at Node B. With the loop suppressed 100%, M1 microglia fall 96% versus control, and pro-inflammatory cytokines collapse in parallel â€” confirming loop disruption rather than partial attenuation.

---

### Death Pathway Decomposition & Loop Intensity

![Death Decomposition and Loop Intensity](figures/fig3_decomposition.png)

**Bottom:** RGC death decomposed into three pathways at the disease activity peak (not endpoint â€” cascade resolves by t_end). Trans-synaptic coupling (~42â€“50%) is structural and drug-independent; cytokine-direct (~46â€“55%) is fully addressable. This split defines the theoretical maximum achievable drug effect.

**Top:** The composite loop intensity index (M1 Ã— C1q Ã— C3a) is fully suppressed in the treated arm, with loop gain L = 5.45â€“6.6Ã— confirming the supercritical cascade was genuinely self-amplifying â€” not a transient flare.

---

### Microglial States & NTF Neuroprotection

![Microglial States](figures/fig4_microglia.png)

M2 neuroprotective polarisation is preserved and enhanced under treatment as pro-inflammatory cytokine pressure falls. The NTF (BDNF/IGF-1) arm rises in treated animals as M2 recovers, providing a secondary protective signal through the RGC survival term â€” the virtuous cycle operating in parallel with loop suppression.

---

## Metrics Scorecard

![Scorecard](figures/fig5_scorecard.png)

| Metric | Result | Target |
|--------|--------|--------|
| RGC treated (day 180) | ~59% | > 40% |
| RGC control (day 180) | ~48% | 40â€“65% |
| RGC protection | +11â€“12 pp | â‰¥ 5 pp |
| RPE control (day 180) | ~60% | 25â€“65% |
| Trans-syn frac (peak) | ~42â€“50% | 10â€“45% |
| Cytokine frac (peak) | ~46â€“55% | 15â€“60% |
| Loop suppression | ~100% | â‰¥ 25% |
| Î”M1 drug effect | ~96% | â‰¥ 5% |
| Î”M_mig drug effect | ~63% | â‰¥ 8% |
| Loop gain L | 5.45â€“6.6Ã— | â‰¥ 1Ã— |


---

## Experimental Priority Roadmap

![Experimental Roadmap](figures/fig7_roadmap.png)

Nine experiments ranked by predicted leverage on key model parameters. Each entry specifies the exact quantitative prediction the experiment would validate or falsify.

| Priority | Experiment | Parameter | Leverage |
|----------|-----------|-----------|---------|
| 1 | ATP/DAMP release kinetics from IOP-stressed RPE | k_damp_rpe | ðŸ”´ High |
| 2 | Complement loop gain validation: M1â†’C1qâ†’C3aâ†’M1 time-course | k_C1q_M1 Â· k_C3aR_act â†’ L | ðŸ”´ High |
| 3 | Microglial migration: DAMP vs C5a gradient comparison | k_mig_damp Â· k_mig_C5a | ðŸ”´ High |
| 4 | RPE C3 secretion under pro-inflammatory cytokines | k_C3_rpe | ðŸŸ¡ Medium |
| 5 | Longitudinal OCT + pattern ERG in DBA/2J model | k_rgc_rpe Â· trans-syn fraction | ðŸ”´ High |
| 6 | RPE ablation + peptide rescue â€” pathway dissection | Trans-syn vs cytokine split | ðŸ”´ High |
| 7 | Peptide PD dose-response: all 4 mechanisms ex vivo | Emax Ã— EC50_pep | ðŸ”´ High |
| 8 | M1/M2 + complement panel in NTG aqueous humor | k_M1_cyt Â· k_M2_cyt | ðŸŸ¡ Medium |
| 9 | NTF depletion: BDNF neutralisation + peptide | k_M2_ntf Â· EC50_ntf | ðŸŸ¡ Medium |

---

## Model Architecture

### ODE System (14 state variables)

| # | Variable | Description |
|---|----------|-------------|
| 0 | RPE | Retinal pigment epithelium (fraction surviving) |
| 1 | DAMPs | Danger-associated molecular patterns (HMGB1, ATP) |
| 2 | M0 | Resting microglia pool |
| 3 | M_mig | Migrating / chemotactically activated microglia |
| 4 | M1 | Pro-inflammatory M1 microglia |
| 5 | M2 | Anti-inflammatory / neuroprotective M2 microglia |
| 6 | C3 | Complement C3 tissue pool |
| 7 | C1q | C1q â€” loop amplification node A (produced by M1) |
| 8 | C3a | C3a anaphylatoxin â€” loop closure node B (C3aRâ†’M1) |
| 9 | C5a | C5a â€” drives M_mig recruitment via C5aR1 |
| 10 | Cyt_pro | Pro-inflammatory cytokines (IL-1Î², IL-6, TNF-Î±) |
| 11 | Cyt_anti | Anti-inflammatory cytokines (IL-4, IL-10) |
| 12 | NTF | Neurotrophic factors (BDNF, IGF-1) â€” M2-secreted |
| 13 | RGC | Retinal ganglion cells (fraction surviving) |

Plus 2 PK compartments: `A_eye` (intravitreal depot) and `C_pep` (active peptide).

### Three Coupled Feedback Cycles

| Loop | Nodes | Type | Drug target |
|------|-------|------|-------------|
| Complement amplifier | M1â†’C1qâ†’C3â†’C3aâ†’C3aRâ†’M1 | ðŸ”´ Vicious amplifier (L=5.5Ã—) | PD1: C1q block; PD2: C3aR block |
| RPEâ€“DAMPâ€“cytokine | RPE deathâ†’DAMPsâ†’M_migâ†’M1â†’Cytâ†’RPE death | ðŸ”´ Vicious amplifier | PD3: M1â†’M2 switch; PD4: migration block |
| M2â€“NTF protective | M2â†’NTFâ†’RGC survivalâ†’â†“DAMPâ†’M2 | ðŸ’š Virtuous cycle | Preserve â€” drug indirectly enhances via M2 recovery |

### Key Design Decisions

**Two RGC death pathways with different drug accessibility:**

```
// Trans-synaptic (structural â€” drug-INDEPENDENT)
d_rpe = k_rgc_rpe Ã— (1 âˆ’ RPE)      â† RPE loss withdraws trophic support

// Cytokine-direct (inflammatory â€” drug-ACCESSIBLE)
d_cyt = k_rgc_cyt Ã— Cyt_pro        â† M1-derived IL-1Î²/TNF-Î± kill RGC

// RGC survival
dRGC/dt = âˆ’(d_cyt + d_rpe + d_iop) Ã— (1 âˆ’ NTF_prot) Ã— RGC
```

The trans-synaptic pathway (~42â€“50% of peak death rate) cannot be addressed by any anti-inflammatory mechanism. This defines the theoretical drug efficacy ceiling and explains why large upstream M1 suppression (~96%) produces moderate RGC protection (+11â€“12 pp).

**v5 TLR4/NF-ÎºB bootstrap (Â§6.3.1):**
A low-efficiency DAMPâ†’M1 ignition route (`k_damp_M1 Ã— DAMPs Ã— M_mig â†’ M1`) primes the cascade before the C1q amplification loop takes over â€” solving the "cold-start" problem where the loop cannot self-ignite from rest.

```
// Bootstrap (ignition before loop activates)
tlr4_M1 = k_damp_M1 Ã— DAMPs Ã— M_mig

// Loop closure (dominant once C1q accumulates)
c3ar_M1 = k_C3aR_act Ã— C3a Ã— M_mig Ã— (1 âˆ’ Pd_C3aR)

dM1/dt = tlr4_M1 + c3ar_M1 âˆ’ k_M1_switch Ã— (1 + Pd_sw) Ã— M1 âˆ’ k_deact_M1 Ã— M1
```

**Loop gain L must exceed 1 for a self-sustaining cascade:**

```
L = (k_C1q_M1 Ã— k_C3_cleave Ã— C3_ss Ã— k_C3a_frac Ã— k_C3aR_act Ã— M_mig_peak)
    Ã· (k_C1q_deg Ã— k_C3a_deg Ã— (k_M1_switch + k_deact_M1))

Default parameters: L â‰ˆ 0.26 (subcritical â€” cascade decays)
After calibration:  L â‰ˆ 5.5â€“6.6Ã— (supercritical â€” self-sustaining)
```

**Death fractions measured at peak, not endpoint:**
By t_end the cascade has resolved â€” M1 â‰ˆ 0, Cyt_pro â‰ˆ 0 â€” making the endpoint cytokine fraction appear near-zero even when it dominated during active disease. All biological targets are evaluated at the peak total RGC death rate (typically days 15â€“60).


---

## Features

- âš¡ **Full in-browser RK4 solver** â€” zero installation, runs on any device
- ðŸ”¬ **Pre-ODE loop screening** â€” matrix classifier with validation
- âš™ï¸ **ODE generator** â€” auto-writes JS, R, and mathematical equations for each loop classification
- ðŸ¤– **Auto-optimiser** â€” 10-rule cascade calibrating to 6 biological targets with loop gain priority (R0)
- ðŸ“Š **Loop gain diagnostic** â€” live L calculation, colour-coded âœ“/âœ— in stat cards and target bar
- ðŸ•¸ **Interactive signalling network** â€” vis.js SimBiology-style graph, drag-and-drop editable
- ðŸ“ˆ **10 Plotly charts** â€” RGC/RPE survival, complement loop nodes, microglial states, death decomposition
- ðŸ§ª **Experimental priority roadmap** â€” 9 experiments ranked by model leverage, rendered live from data
- ðŸ“„ **PDF export** â€” results report with all charts and parameter table, no code
- ðŸ“¦ **Export R / deSolve script** â€” complete runnable model generated from current slider state

---

## Access

**The source code for this tool is available on request.**

> âš ï¸ Unauthorised copying, redistribution, or modification of the source code is prohibited.  
> Â© 2025 tjmb03. All rights reserved.

---

*Built with Plotly.js Â· vis-network Â· pure in-browser RK4 Â· jsPDF Â· html2canvas*
